Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache

July 4, 2014 updated by: Boehringer Ingelheim

A Randomised, Double Blind, Placebo- and Active-controlled Parallel Group Study Investigating the Efficacy and Tolerability of Metamizol 0.5 g and 1.0 g in Patients With Episodic Moderate Tension Headache.

The objective of the study was to evaluate the efficacy, safety and tolerability of a single peroral dose of 0.5 g and 1.0 g metamizol relative to placebo and 1.0 g acetylsalicylic acid in 2 episodes of moderate tension headache.

Study Overview

Study Type

Interventional

Enrollment (Actual)

417

Phase

  • Phase 3

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male and female patients between 18 and 65 years old
  • Moderate episodic tension headache according to International Headache Society (I.H.S.) classification 2.1 (2.1.1 and 2.1.2) for at least one year
  • At least two episodes of tension headache per month in the last three months prior to enrolment into this trial
  • The episodes of tension headaches were usually treated by the patient successfully with a non-opioid-analgesic
  • First episodic headache occurred at an age under 50 years
  • Written informed consent according to Good Clinical Practice (GCP) and local regulations
  • The patient was able to fill in the Patient's Diary

Exclusion Criteria:

  • The patient usually needs for successful treatment of tension headache "Over The Counter" (OTC) analgesic in doses exceeding the doses tested here
  • The patient takes an OTC-analgesic normally at the first signs of an episode of tension headache
  • The patient has more than 15 episodes of tension headache per month
  • Female patients whose episodic tension headache is strongly correlated with the start of hormonal contraception
  • Concomitant treatment with (non-) prescriptional analgesics
  • Pre- (less than 4 weeks prior to inclusion in this trial) and/or concomitant treatment with an antidepressive and/or antipsychotic drug
  • Pre- (less than 2 weeks prior to inclusion in this trial) and/or concomitant treatment with any drug such as NSAIDs (Non-Steroidal Anti Inflammatory Drugs), propanolol, metroprolol, flunarizin, cyclandelate, valproic-acid, serotonergic antagonists, ergotamine, dihydroergotamines and benzodiazepines that may influence the headache symptomatology
  • Use of benzodiazepines in the previous 24 hours to the administration of the study drug. Occasional use of benzodiazepines - up to 3 per week - is allowed
  • Use of any drug with analgesic properties in the previous 24 hours to the administration of the study drug
  • Concomitant treatment with any drug containing ASA and/or metamizol
  • Concomitant treatment with anticoagulants such as heparin or coumarin-derivatives
  • Alcohol and drug abuse according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders )
  • Female patients in child-bearing age not using adequate means of birth control
  • Pregnancy and/or lactation
  • Gastrointestinal ulcers
  • Liver and/or renal disease
  • Bronchial asthma
  • Relevant allergy or known hypersensitivity to the investigational drugs, its excipients and/or to other NSAIDs
  • Participation in another clinical trial within the last 4 weeks and concurrent participation in another clinical trial
  • Patients with active gastroesophageal flux disease (Amendment number 1)
  • Concomitant treatment with analgesics or any other drug that may have influenced the headache symptomatology - including metamizol or ASA -, was referred to its use during the headache episodes under evaluation. As long as appropriate wash-out periods were respected, analgesics were allowed in between the episodes of tension headache (TH) and their use as a rescue medication did not lead to the exclusion of the patient (Amendment number 2)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Experimental: Metamizol high & Placebo
Experimental: Metamizol low & Placebo
Active Comparator: Acetylsalicylic acid & Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Time-interval weighted sum of pain intensity difference (SPID) on a Visual Analogue Scale (VAS)
Time Frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
before and 30 minutes, 1, 2, 3, and 4 hours after drug intake

Secondary Outcome Measures

Outcome Measure
Time Frame
Pain intensity difference (PID) on a VAS
Time Frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
Maximum pain intensity difference (MAXPID) on a VAS
Time Frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
Number of patients with at least a 50% pain reduction on a VAS
Time Frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
Time to 50% pain intensity reduction on a VAS
Time Frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
Maximum pain relief (MAXPAR) on a Verbal Rating Scale (VRS)
Time Frame: 30 minutes, 1, 2, 3, and 4 hours after drug intake
30 minutes, 1, 2, 3, and 4 hours after drug intake
Total pain relief (TOTPAR) on a VRS
Time Frame: 30 minutes, 1, 2, 3, and 4 hours after drug intake
30 minutes, 1, 2, 3, and 4 hours after drug intake
Number of patients using rescue medication
Time Frame: 2, 3, and 4 hours after drug intake
2, 3, and 4 hours after drug intake
Global efficacy assessment on a VRS by the patient and investigator
Time Frame: 4 hours after drug intake
4 hours after drug intake
Number of patients with adverse events
Time Frame: up to 2 months
up to 2 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 1998

Primary Completion (Actual)

July 1, 1999

Study Registration Dates

First Submitted

July 4, 2014

First Submitted That Met QC Criteria

July 4, 2014

First Posted (Estimate)

July 8, 2014

Study Record Updates

Last Update Posted (Estimate)

July 8, 2014

Last Update Submitted That Met QC Criteria

July 4, 2014

Last Verified

July 1, 2014

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Migraine Disorders

Clinical Trials on Metamizol

3
Subscribe